UNIVERSITY OF WASHINGTON;The General Hospital Corporation;MASSACHUSETTS INSTITUTE OF TECHNOLOGY
发明人:
Randall T. Moon,Travis L. Biechele,Nathan D. Camp,Stephen Haggarty,Daniel Fass
申请号：
US14082810
公开号：
US20140080775A1
申请日:
2013.11.18
申请国别(地区):
US
年份:
2014
代理人:
摘要：
The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject at least one compound selected from the group consisting of those set forth in Table 1, Table 2, Table 3, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.
